Investors

Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.

Latest results

Portfolio metrics

35+
Approved products
12
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration

Financial metrics

$2.8bn
Portfolio Receipts
(2022)
$2.6bn
Adjusted EBITDA
(2022)
$2.2bn
Average annual capital deployed (2017-2022)
$3.5bn
Announced value of transactions (2022)

Corporate presentation

SEC filings

Filing Date Form View
Loading…
All Filings

Latest releases

Royalty Pharma Announces Dividend Increase

NEW YORK, NY, January 19, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend.

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe